Free Webex Call
The Plasma Fractionation Market was valued at USD 25.78 Billion in 2024, and is expected to reach USD 36.82 Billion by 2030, rising at a CAGR of 6.32%. This growth is driven by the increasing reliance on plasma-derived therapies to manage chronic and rare conditions, including hemophilia, primary immunodeficiency disorders, and neurological diseases like Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The expanding elderly population and a higher prevalence of immune-related and bleeding disorders are contributing to the steady demand for plasma-based products such as immunoglobulins, albumin, and clotting factors. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The continuous development of plasma collection infrastructure, especially across emerging economies, is further supporting market expansion. However, challenges such as high production costs, complex regulations, and prolonged manufacturing timelines hinder scalability. Additionally, competition from recombinant and biologic alternatives presents a threat to traditional plasma-based therapies.
Key Market Drivers
Growth in Healthcare Industry
The consistent expansion of the global healthcare industry is a fundamental driver of the plasma fractionation market. Generating more than USD 4 trillion annually, the industry sees strong contributions from pharmaceuticals and biotechnology at nearly USD 850 billion, and from diagnostics and medical technology at over USD 400 billion. These investments, along with improved infrastructure and wider access to services, are supporting the increasing use of plasma-derived treatments for conditions like immunodeficiencies, hemophilia, liver disease, and trauma-related bleeding.By 2026, hospitals worldwide are projected to number 215,977, with growth mainly concentrated in the Far East & China and the Middle East & Africa. The expansion of hospitals and specialty clinics - especially in developing regions - is enhancing plasma collection and processing capabilities. This development is enabling a more stable global supply of fractionated products, while the rise in outpatient and personalized care models is also accelerating the adoption of these therapies.
Key Market Challenges
Limited Plasma Supply & Donation Infrastructure
A critical challenge in the plasma fractionation market is the limited availability of plasma due to underdeveloped donation systems. Plasma serves as the raw material for essential therapies such as immunoglobulins and clotting factors, yet its supply remains constrained by low donor participation and inconsistent infrastructure - particularly in lower-income countries.In many regions, plasma collection systems are sparse or nonexistent, leading to an imbalance between growing therapeutic demand and available plasma volumes. Plasmapheresis procedures require specialized equipment, skilled staff, and time, which further limits capacity and scalability, especially in resource-limited settings.
Key Market Trends
Increasing Use of Plasma Fractionation in Autoimmune and Neurological Disorders
With over 57 million liters of plasma used annually to produce critical treatments, demand for plasma-derived therapies continues to climb - especially in managing autoimmune and neurological disorders. Conditions such as CIDP, Guillain-Barré syndrome, multiple sclerosis, and myasthenia gravis are increasingly treated with fractionated products, particularly intravenous immunoglobulin (IVIG), due to its immunomodulatory benefits.IVIG has become a standard therapy for many of these conditions, backed by its inclusion in treatment guidelines and proven efficacy. Moreover, its use is expanding beyond conventional applications to address refractory cases and relapse prevention, reinforcing its growing role in neurology and chronic care management.
Key Market Players
- Grifols S.A.
- Octapharma AG
- Intas Pharmaceuticals Ltd
- LFB S.A.
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Biotest AG
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Bharat Serums and Vaccines Limited
Report Scope
In this report, the Global Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:Plasma Fractionation Market, By Product:
- Albumin
- Immunoglobulins
- Coagulation Factors
- Protease Inhibitors
- Others
Plasma Fractionation Market, By Application:
- Neurology
- Hematology
- Oncology
- Immunology
- Others
Plasma Fractionation Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Plasma Fractionation Market.Available Customizations
With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.Company Information
- Detailed analysis and profiling of additional market players (up to five).
This product will be delivered within 1-3 business days.
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
5. Global Plasma Fractionation Market Outlook
6. North America Plasma Fractionation Market Outlook
7. Europe Plasma Fractionation Market Outlook
8. Asia Pacific Plasma Fractionation Market Outlook
9. South America Plasma Fractionation Market Outlook
10. Middle East and Africa Plasma Fractionation Market Outlook
11. Market Dynamics
12. Market Trends & Developments
15. Porters Five Forces Analysis
16. Competitive Landscape
Companies Mentioned
- Grifols S.A.
- Octapharma AG
- Intas Pharmaceuticals Ltd
- LFB S.A.
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Biotest AG
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Bharat Serums and Vaccines Limited
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 185 |
Published | June 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 25.78 Billion |
Forecasted Market Value ( USD | $ 36.82 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |